Clinical Trials Directory

Trials / Sponsors / CG Oncology, Inc.

CG Oncology, Inc.

Industry · 8 registered clinical trials — 1 currently recruiting.

StatusTrialPhaseStarted
RecruitingPhase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
High-Risk Non-Muscle-Invasive Bladder Cancer
Phase 22024-09-16
Active Not RecruitingA Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer
Phase 32023-12-14
CompletedStudy of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive t
Non Muscle Invasive Bladder Cancer
Phase 22020-12-08
Active Not RecruitingStudy of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Ca
Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer
Phase 32020-10-27
CompletedSafety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade NMIBC After BCG Failure
Bladder Cancer
Phase 22015-06-02
TerminatedEfficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer
Transitional Cell Carcinoma, Bladder Cancer, Carcinoma in Situ
Phase 2 / Phase 32014-03-01
WithdrawnSafety and Efficacy of CG0070 Oncolytic Virus Regimen in Patients With High Grade Non-Muscle Invasive Bladder
Bladder Cancer, High Grade, Non Muscle Invasive
Phase 22014-03-01
AvailableAn Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive
Non-Muscle Invasive Bladder Cancer, Urothelial Carcinoma, Urologic Cancer
——